Aimee Vaccine Co., Ltd. announced that it has formally submitted the clinical trial application for the quadrivalent MDCK cell flu virus vaccine to the Drug Evaluation Center (CDE) of China's National Medical Products Administration in August 2024. The vaccine uses MDCK cell culture technology, which can effectively respond to flu virus mutations and has the advantages of short production cycle, stable raw material supply, and low contamination risk. This vaccine is suitable for people aged 6 months and above, especially those susceptible to flu and at high risk, such as children and the elderly. This innovation by Aimee Vaccine will help meet public health needs and may have a significant impact on the flu vaccine market. Currently, the size of the flu vaccine market in China is expected to reach around 20 billion yuan by 2030.

Aimee Vaccine Co., Ltd. announced that it has formally submitted the clinical trial application for the quadrivalent MDCK cell flu virus vaccine to the Drug Evaluation Center (CDE) of China's National Medical Products Administration in August 2024. The vaccine uses MDCK cell culture technology, which can effectively respond to flu virus mutations and has the advantages of short production cycle, stable raw material supply, and low contamination risk. This vaccine is suitable for people aged 6 months and above, especially those susceptible to flu and at high risk, such as children and the elderly. This innovation by Aimee Vaccine will help meet public health needs and may have a significant impact on the flu vaccine market. Currently, the size of the flu vaccine market in China is expected to reach around 20 billion yuan by 2030.